Westmount Partners
MRNA icon

Westmount Partners’s Moderna MRNA Stock Holding History

Westmount Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$334K Buy
+1,767
New +$190K 0.07% 194

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Westmount Partners's MRNA Position: Q3 2026 in Review

Westmount Partners opened a new position in Moderna (MRNA) in Q3 2026: 1,767 shares worth $334K. The stake represents 0.07% of the portfolio and ranks #194 among its holdings.

844 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Westmount Partners held 1,767 shares of Moderna worth $334K as of Q3 2026.
  • Moderna was a new Westmount Partners position in Q3 2026.
  • Moderna made up 0.07% of Westmount Partners's portfolio in Q3 2026, its #194 holding.
  • 844 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Westmount Partners's 13F filing for Q3 2026, filed 12 Nov 2026.